mdlinx mdlinx
Latest (19) Full Text Articles (287) Focus on Rheumatoid Arthritis Article Summary

Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors
Modern Rheumatology,

Kita J et al. – Delayed treatment with tumor necrosis factor (TNF) inhibitors is effective and tolerable for patients with very early rheumatoid arthritis (RA) with poor prognosis factors.

Methods
  • The authors examined 22 patients with very early RA who were positive for anti–cyclic citrullinated peptide antibodies or IgM–rheumatoid factor.
  • The mean disease duration at entry was 14.1 weeks.
  • A treat–to–target strategy, aiming at simplified disease activity index (SDAI) remission, was initiated with synthetic DMARDs.

Results
  • SDAI remission was not achieved in 9 of the 22 patients with synthetic DMARDs alone, and TNF inhibitors were added in these patients.
  • SDAI values in these 9 patients were further examined for the following 6 months.
  • The TNF inhibitors (infliximab 8, etanercept 1) were added at a mean interval of 34.1 weeks after the initiation of synthetic DMARDs.
  • SDAI remission was achieved in 4 of the 9 patients (44.4%) at 3 months and in 8 of the 9 patients (88.9%) at 6 months after the introduction of the TNF inhibitors.
  • Radiographic damage had not progressed in these patients.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

Last month's top read Top Articles of 2013

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Other Topics in Rheumatology

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Stay current - Media Tool

Newsletter
RSS
Follow
Like

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close